Cardiff Oncology Inc (NASDAQ: CRDF) is 26.53% higher on its value in year-to-date trading and has touched a low of $2.01 and a high of $5.64 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The CRDF stock was last observed hovering at around $3.20 in the last trading session, with the day’s loss setting it -2.01%.
Currently trading at $1.19M, the stock is -12.29% and -0.17% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.55 million and changing 1551538% at the moment leaves the stock -6.07% off its SMA200. CRDF registered -28.57% loss for a year compared to 6-month loss of -30.96%. The firm has a 50-day simple moving average (SMA 50) of $3.1054 and a 200-day simple moving average (SMA200) of $3.30055.
The stock witnessed a 2.31% gain in the last 1 month and extending the period to 3 months gives it a -18.42%, and is -16.22% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 2.61% over the week and 6.51% over the month.
Cardiff Oncology Inc (CRDF) has around 33 employees, a market worth around $206.23M and $0.59M in sales. Profit margin for the company is -8312.59%. Distance from 52-week low is 54.23% and -45.03% from its 52-week high. The company has generated returns on investments over the last 12 months (-68.35%).
The EPS is expected to grow by 15.19% this year
144.0 institutions hold shares in Cardiff Oncology Inc (CRDF), with institutional investors hold 47.99% of the company’s shares. The shares outstanding are 66.53M, and float is at 60.75M with Short Float at 29.03%. Institutions hold 45.29% of the Float.
The top institutional shareholder in the company is BLACKROCK INC. with over 2.63 million shares valued at $5.84 million. The investor’s holdings represent 5.8637 of the CRDF Shares outstanding. As of 2024-06-30, the second largest holder is VANGUARD GROUP INC with 2.14 million shares valued at $4.74 million to account for 4.766 of the shares outstanding. The other top investors are ASSENAGON ASSET MANAGEMENT S.A. which holds 1.22 million shares representing 2.7126 and valued at over $2.7 million, while GEODE CAPITAL MANAGEMENT, LLC holds 2.0316 of the shares totaling 0.91 million with a market value of $2.02 million.
Cardiff Oncology Inc (CRDF) Insider Activity
The most recent transaction is an insider purchase by Levine James E., the company’s Chief Financial Officer. SEC filings show that Levine James E. bought 2,752 shares of the company’s common stock on Dec 17 ’24 at a price of $5.42 per share for a total of $14905.0. Following the purchase, the insider now owns 65316.0 shares.
Cardiff Oncology Inc disclosed in a document filed with the SEC on Dec 18 ’24 that Levine James E. (Chief Financial Officer) bought a total of 2,400 shares of the company’s common stock. The trade occurred on Dec 18 ’24 and was made at $5.00 per share for $12000.0. Following the transaction, the insider now directly holds 67716.0 shares of the CRDF stock.
Still, SEC filings show that on Dec 16 ’24, Levine James E. (Chief Financial Officer) acquired 2,564 shares at an average price of $3.83 for $9820.0. The insider now directly holds 62,564 shares of Cardiff Oncology Inc (CRDF).
